Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2008-07-08
2008-07-08
Helms, Larry R. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S387300, C530S387500, C530S388150, C530S388240, C530S389200
Reexamination Certificate
active
07396917
ABSTRACT:
Antibodies or fragments thereof having at least two CDR regions replaced or fused with biologically active peptides are described. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.
REFERENCES:
patent: 4642334 (1987-02-01), Moore et al.
patent: 4783330 (1988-11-01), Furie et al.
patent: 4816397 (1989-03-01), Boss et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5219996 (1993-06-01), Bodmer et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5260417 (1993-11-01), Grant et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5571698 (1996-11-01), Ladner et al.
patent: 5593666 (1997-01-01), McDonald
patent: 5698435 (1997-12-01), Robinson et al.
patent: 5750373 (1998-05-01), Garrard et al.
patent: 5773569 (1998-06-01), Wrighton et al.
patent: 5837500 (1998-11-01), Ladner et al.
patent: 5869451 (1999-02-01), Dower et al.
patent: 5874253 (1999-02-01), Tsujimoto et al.
patent: 5876961 (1999-03-01), Crowe et al.
patent: 5885574 (1999-03-01), Elliott
patent: 5919758 (1999-07-01), Sytkowski
patent: 5932546 (1999-08-01), Barrett et al.
patent: 5965405 (1999-10-01), Winter et al.
patent: 5969108 (1999-10-01), McCafferty et al.
patent: 6008023 (1999-12-01), Opper et al.
patent: 6040136 (2000-03-01), Garrard et al.
patent: 6162902 (2000-12-01), Mischak et al.
patent: 6172197 (2001-01-01), McCafferty et al.
patent: 6342220 (2002-01-01), Adams et al.
patent: 6660843 (2003-12-01), Feige et al.
patent: 6677124 (2004-01-01), Tsuji et al.
patent: 6737249 (2004-05-01), Adams et al.
patent: 6936440 (2005-08-01), Cunningham et al.
patent: 7081523 (2006-07-01), Elliott
patent: 2003/0162710 (2003-08-01), Sudoh et al.
patent: 1642910 (2006-04-01), None
patent: WO 94/18221 (1994-08-01), None
patent: WO-9511317 (1995-04-01), None
patent: WO-9529690 (1995-11-01), None
patent: WO-9640189 (1996-12-01), None
patent: WO-9640750 (1996-12-01), None
patent: WO-9910494 (1999-03-01), None
patent: WO-9925378 (1999-05-01), None
patent: WO-0024782 (2000-05-01), None
patent: WO-0061637 (2000-10-01), None
patent: WO-02/46238 (2002-06-01), None
patent: WO-02078612 (2002-10-01), None
Barbas et al (b) (PNAS 92:2529-2533, 1995).
Kini et al (FEBS Letters 375:15-17, 1995).
Colman et al (Research in Immunology 1994, 145:33-36).
Rudikoff et al (Proc. Natl. Acad. Sci. USA 1982 vol. 79 p. 1979).
Ibragimova and Eade (Biophysical Journal, Oct. 1999, vol. 77, pp. 2191-2198).
Burgess et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue,” Journal of Cell Biology, 111:2129-2138 (1990).
Clemens et al. “Human Brain Natriuretic Peptide Reduces Blood Pressure in normotensive and Acute Norepinephrine-Induced Hypertensive Rabbits” 1997, American Journal of Hypertension vol. 10 pp. 654-664.
De Serres et al., “Pharmacokinetics and Hematological Effects of the PEGylated Thrombopoietin Peptide Mimetic GW395058 in Rats and monkeys After Intravenous or Subcutaneous Administration,” Stem Cells, 17(6):316-326 (1999).
Fukui et al., “A New Thiazolodinedione, NC-2100, Which is a Weak PPAR-gamma Activator, Exhibits Potent Antidiabetic Effects and Induces Uncoupling Protein 1 in White Adipose Tissue of KKAY Obese Mice,” Diabetes 49:759-767 (2000).
Ibragimova et al., “Stability of the β-Sheet of the WW Domain: A Molecular Dynamics Simulation Study,” Biophysical Journal, 77:2191-2198 (1999).
Johnson et al., “Identification of a 13 Amino Acid Peptide Mimetic of Erythropoietin and Description of Amino Acids Critical for the Mimetic Activity of EMP1,” Biochemistry, 37:3699-3710 (1998).
Lazar et al., “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,” Molecular and Cell Biology, 8(3):1247-1252 (1998).
Lin et al. “Structure Function Relationships in Glucagon: Properties of Highly Purified Des-His1-, Monoiodo-, and [Des-Asn 28, Thr29](homoserine lactone27) glucagon,” Biochemistry USA, 14:1559-1563 (1975).
Montrose-Rafizadeh et al., “High Potency Antagonists of the Pancreatic Glucagon-like Peptide-1 Receptor,” The Journal of Biological Chemistry, 272(34):21201-21206 (1997).
Mukoyama et al. “Brain Natriuretic Peptide as a Novel Cardiac Hormone in Humans”, Apr. 1991, J. Clinical Investigation vol. 87 pp. 1402-1412.
Rayburn et al., “Nesiritide: A Unique Therapeutic Cardiac Peptide,” Reviews in Cardiovascular Medicine, 2(2):S25-S31 (2001).
Roch et al.,, “Altered methional homoeostasis is associated with decreased apoptosis in BAF3 bcl2 murine lymphoid cells,” Biochem, 313:973-981 (1996).
Schwartz et al. “A superactive insulin: [B10-Aspartic acid] insulin (human),” Proc. Natl. Acad. Sci. USA, 84:6408-6411 (1987).
Wrighton et al., “Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin,” Science, 273:458-463 (1996).
Johnson et al., “Erythropoietin mimetic peptide and the future,” Nephrology Dialysis Transplantation, 15:1274-1277(2000).
Li et al., “Expression of TPO mimetic peptide chimeric proteins with human IgG1 Fc fragments and their biological characters,” Sheng Wu Gong Cheng Xue Bao = Chinese Journal of Biotechnology, 18(4):424-430(2002).
Supplementary European Search Report from Application No. EP 03786822, dated Jun. 21, 2006.
Frederickson et al., “A rationally designed agonist antibody fragment that functionally mimics thrombopoietin,” PNAS 103(39):14307-14312 (2006).
Alfthan, Kaija, et, al. “Properties of a single-chain antibody containing different linker peptides”. 1995. Protein Engineering vol. 8, No. 7, pp. 725-731.
Barbas III, Carlos F., et, al. “Assembly of combinatorial antibody libraries on phage surfaces: The gene III site”. Sep. 1991. Proc. Natl. Acad. Sci. USA Biochemistry. vol. 88, pp. 7978-7982.
Barbas, Shana M., et, al. “Human autoantibody reconition of DNA”. Mar. 1995. Proc. Natl. Acad. Sci. USA. vol. 92, pp. 2529-2533.
Barbas, Shana M., et, al. “Recognition of DNA by Synthetic Antibodies”. Nov. 10, 1993. J. AM. Chem. Soc., vol. 116, No. 5 pp. 2161-2162.
Better, Marc, et, al. “Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2”. Jan. 1993, Proc. Natl, Acad. Sci. USA, vol. 90, pp. 457-461, Immunology.
Burton, Dennis R., et, al. “Human Antibodies from Combinatorial Libraries”. 1994, Advances in Immunology, vol. 57, pp. 191-280.
Carlson, John R., et al., “Molecular Tools for Inactivating a Yeast Enzyme In Vivo”. Jun. 1988, Molecular and Cellular Biology, vol. 8, No. 6 pp. 2547-2650.
Carter, Paul, et, al. “High levelEscherichia coliexpression and production of a bivalent humanized antibody fragment” Bio/Technology vol. 10 pp. 163-167, 1992.
Chaiken I M et al., Identifying Structure-Function Relationships in Four-Helix Bundle Cytokines: Towards De Nova Mimetics Design, Trends in Biotechnology, Elsevier Publications Cambridge, GB, vol. 14, No. 10, Oct. 1, 1996, pp. 369-375.
Cook, Jeremy, Recombinant Antibodies Containing an Engineered B-Cell Epitope Capable of Eliciting Conformation-Specific Antibody Responses, Butterworth Heinemann, Vaccine, vol. 13, No. 18, pp. 1770-1778, 1995, Esevier Science Ltd.
Cwirla, Steven E., et. al., “Peptide Agonist of the Thrombopoietin Receptor as Potent as the Natural Cytokine”, Jun. 13, 1997, Science, vol. 276 pp. 1696-1699.
de Kruif, John, et, al. “Leucine zipper Dimerized Bivalent and Bispecific scFv Antibodies from a Semi-synthetic Antibody Phage Display Library”. Mar. 29, 1996. The J. of Biological Chemistry, vol. 271, No. 13, pp. 7630-7634.
de Sauvage, Frederic J., et, al. “Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligant
Bowdish Katherine S.
Frederickson Shana
Renshaw Mark
Alexion Pharmaceuticals, Inc.
Helms Larry R.
Ropes & Gray LLP
Tungaturthi Parithosh K.
LandOfFree
Rationally designed antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Rationally designed antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rationally designed antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2749492